PREDICTOM is inviting general practitioners to take part in our survey. With the aim of identifying current clinical guidelines and practice for screening, identifying and diagnosing Alzheimer's Disease and early dementia, we want to hear your views.
Photo: Svein Lunde, Helse Stavanger
Published 10 February 2025
Share this article
We are inviting general practitioners to complete this short survey. It should take around 10 minutes to complete. We want to hear about your current clinical practice when managing patients who you suspect have dementia. We also ask some questions about Alzheimer’s disease and mild cognitive impairment.
Your responses will help us develop recommendations for optimising clinical practice guidelines, considering new technologies to support diagnosis and facilitators and barriers to implementation in primary care settings.
The PREDICTOM is pleased to announce the launch of Level 2 of its international clinical study—an important next step made possible entirely through the generosity, time, and commitment of participants across Europe. The participants' contributions continue to drive forward our shared goal: improving the early detection of Alzheimer’s disease through accessible, reliable, and science-driven tools.
A single drop of blood may soon help identify Alzheimer’s disease - even before symptoms appear. Researchers from the PREDICTOM study are exploring a simple, cost-effective finger-prick test that measures a breakthrough biomarker called p-Tau217, offering hope for earlier and more accessible screening. The finger-prick test is included in PREDICTOM Level 1 clinical study.
